Filter by: patients
What is Benazepril?

Benazepril is an ACE inhibitor medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
Elevated blood pressure 22 5 Efficacy_major Efficacy_moderate Efficacy_cant_tell
Hypertension 5 0
Other 3 0
General health 2 0
Support circulatory health 1 1 Efficacy_moderate
support kidney function 1 0

See all 32 patients currently taking Benazepril

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
0
Moderate
0
Mild
0
None
6

Reported Dosages

  5 mg daily 10 mg daily 12.5 mg daily 20 mg daily 30 mg daily 40 mg daily
  3 Number of Patients: 3 4 Number of Patients: 4 1 Number of Patients: 1 14 Number of Patients: 14 2 Number of Patients: 2 10 Number of Patients: 10  

Reported Stop Reasons

Why Patients Stopped Taking Benazepril (multiple reasons could be selected)
Reason # Patients Percentage of patients
Doctor's advice 7   Doctor's advice: 78%
Other 2   Other: 22%
Side effects too severe 1   Side effects too severe: 11%

See all 9 patients who’ve stopped taking Benazepril

Currently Taking Benazepril

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Stopped Taking Benazepril

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0

Reported Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Adherence of Benazepril

Always
5 83%
Usually
1 17%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Burden of Benazepril

Very
0 0%
Somewhat
0 0%
A little
1 17%
Not at all
5 83%

Cost

Paid out of pocket

Cost of Benazepril

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
2 40%
< $25
3 60%

See more information, including instructions, precautions, side effects, and interactions.

Report created on February 11, 2012.